-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Underweight on Oscar Health, Lowers Price Target to $11

Benzinga·07/23/2025 13:00:57
Listen to the news
Barclays analyst Andrew Mok maintains Oscar Health (NYSE:OSCR) with a Underweight and lowers the price target from $17 to $11.